Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Terlipressin intravenous - Orphan Therapeutics

Next Previous
Drug Profile

Terlipressin intravenous - Orphan Therapeutics

Alternative Names: Lucassin; TERLIVAZ

Latest Information Update: 28 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orphan Therapeutics LLC
  • Developer Mallinckrodt plc; Orphan Therapeutics
  • Class Antidiuretics; Antihaemorrhagics; Peptides; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatorenal syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatorenal syndrome

Most Recent Events

  • 11 Nov 2023 Pooled efficacy data from a phase-III OT0401, REVERSE and CONFIRM trials in Hepatorenal syndrome presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD -2023)
  • 10 Nov 2023 Pooled efficacy data from a phase-III REVERSE and CONFIRM trials in Hepatorenal syndrome presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD -2023)
  • 10 Nov 2023 Efficacy data from a phase III CONFIRM trial in Hepatorenal Syndrome presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top